Medical Marijuana Sciences' Scientific Advisory Board Chairman Dr. Mark L. Rabe Educates Professional Fiduciaries on the Bene...
April 28 2014 - 9:00AM
Medical Marijuana Sciences, Inc. (MMS), a subsidiary of Nuvilex,
Inc. (OTCQB:NVLX), a clinical stage international biotechnology
company providing cell and gene therapy solutions for the treatment
of diseases, announced today that Mark L. Rabe, MD, ABIHM, the
Scientific Advisory Board Chairman of MMS, addressed conservators,
guardians and trustees at the Professional Fiduciary Association of
California (PFAC) Educational Conference in San Diego as part of
the Medical Marijuana Education Session that occurred at the PFAC
Educational Conference on April 25, 2014, where he discussed the
medical benefits of the components of Cannabis (Marijuana).
Dr. Rabe's presentation detailed how Cannabis plant-based
molecules, such as THC (tetrahydrocannabinol) and CBD
(cannabidiol), provide broad medicinal benefits as their molecular
structures are similar to "endocannabinoid" molecules.
Endocannabinoid molecules occur naturally in the human body and
regulate multiple systems. Dr. Rabe referred to research which
documents the pain-relieving, anti-oxidative, neuroprotective and
anti-cancer effects of THC, CBD and other cannabinoids that make
them potentially useful in the treatment of a variety of medical
conditions.
"It is gratifying to see the strong level of interest in
medicinal Cannabis shown by professional organizations, such as
PFAC, in order to serve the best interest of their clients,"
commented Dr. Rabe. "Our work at Medical Marijuana Sciences
may further broaden patient options with respect to
cannabinoid-based therapies, particularly in the treatment of
deadly diseases like pancreatic and brain cancers. Now that
the MMS Scientific Advisory Board has successfully defined our
initial lines of investigation, we anticipate moving forward with
formal preclinical research soon," he continued.
Dr. Rabe spoke about the future of a plant that has been used as
a medicine for thousands of years, describing how it is Medical
Marijuana Sciences' mission to develop cannabinoid-based treatments
utilizing Nuvilex's Cell-in-a-Box® technology as a bio-sustainable
platform in order to provide targeted cancer chemotherapy.
About Medical Marijuana Sciences:
Medical Marijuana Sciences, Inc. (MMS), a wholly owned
subsidiary of Nuvilex, Inc., is dedicated to the development of
cancer treatments based upon chemical constituents of marijuana
known as cannabinoids. To do so, MMS will examine ways to
exploit the benefits of Cell-in-a-Box® technology in optimizing the
anticancer effectiveness of cannabinoids against cancers while
minimizing or outright eliminating the debilitating side effects
usually associated with cancer treatments. This provides MMS a
unique opportunity to develop "green" approaches to fighting deadly
cancers, such as those of the pancreas, brain, breast and prostate,
that affect hundreds of thousands of individuals worldwide every
year.
About Nuvilex:
Nuvilex, Inc. is a clinical stage biotechnology company focused
on developing and preparing to commercialize treatments for cancer
and diabetes based upon a proprietary cellulose-based live-cell
encapsulation technology known as Cell-in-a-Box®. This unique
and patented technology will be used as a platform upon which
treatments for several types of cancer, including advanced,
inoperable pancreatic cancer, and diabetes are being
built. Nuvilex's treatment for pancreatic cancer involves the
widely used anticancer prodrug ifosfamide, together with
encapsulated live cells, which convert ifosfamide into its active
or "cancer-killing" form. Nuvilex is also involved in clinical
trials related to other aspects of pancreatic and other forms of
cancer.
Safe Harbor:
This press release may contain forward-looking statements
regarding Nuvilex and its future events and results that involve
inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to Nuvilex or its management, are
intended to identify forward-looking statements. Important factors,
many of which are beyond the control of Nuvilex, that could cause
actual results to differ materially from those set forth in the
forward-looking statements include Nuvilex's ability to continue as
a going concern, delays in clinical trials or flaws or defects
regarding its products, changes in relevant legislation or
regulatory requirements, uncertainty of protection of Nuvilex's
intellectual property and Nuvilex's continued ability to raise
capital. Nuvilex does not assume any obligation to update any of
these forward-looking statements.
More information about Medical Marijuana Sciences and Nuvilex
can be found at www.medicalmarijuanasciences.com and
www.nuvilex.com. It can also be obtained by contacting
Investor Relations and Media Contacts.
CONTACT: Investor Relations Contacts:
Marlin Molinaro
Marmel Communications, LLC
Ph: 702.434.8692
mmolinarofc@aol.com
Dillon Heins
CorProminence, LLC
Ph: 218.839.9051
dillonh@corprominence.com
Media Contact:
Jules Abraham
JQA Partners, LLC
Ph: 917.885.7378
jabraham@jqapartners.com